FBT:NYE-First Trust NYSE Arca Biotechnology Index Fund (USD)

ETF | Health |

Last Closing

USD 171.46

Change

-4.01 (-2.29)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-03 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.65 (+0.44%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

+0.11 (+0.16%)

USD 2.77B
FXH First Trust Health Care AlphaD..

-1.11 (-1.04%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-1.29 (-1.46%)

USD 0.20B
IDNA iShares Genomics Immunology an..

-0.58 (-2.58%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-1.34 (-4.28%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-1.53 (-1.57%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.49 (-1.69%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-2.27 (-3.68%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-1.16 (-5.71%)

USD 6.67M

ETFs Containing FBT

FBT:CA First Trust NYSE Arca Bio.. 99.83 % 0.00 %

+0.26 (+0.82%)

CAD 1.83M
FHM:CA 0.00 % 0.78 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.16% 52% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.16% 52% F 69% C-
Trailing 12 Months  
Capital Gain 11.14% 100% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.14% 95% A 64% D
Trailing 5 Years  
Capital Gain 14.47% 38% F 53% F
Dividend Return 1.48% 37% F 4% F
Total Return 15.95% 38% F 39% F
Average Annual (5 Year Horizon)  
Capital Gain 1.22% 38% F 38% F
Dividend Return 1.55% 38% F 29% F
Total Return 0.33% 42% F 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 12.15% 86% B+ 74% C
Risk Adjusted Return 12.73% 38% F 29% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.